Zhou Guo,Jiamin Lin,Kai Sun,Jiayou Guo,Xudong Yao,Genchun Wang,Liangcai Hou,Jingting Xu,Jiachao Guo,Fengjing Guo
Corrigendum: Deferoxamine alleviates osteoarthritis by inhibiting chondrocyte ferroptosis and activating the Nrf2 pathway 10.3389/fphar.2023.1199951
osteoarthritis,chondrocytes,ferroptosis,deferoxamine,Nrf2
Corrigendum: Deferoxamine alleviates osteoarthritis by inhibiting chondrocyte ferroptosis and activating the Nrf2 pathway 10.3389/fphar.2023.1199951

In the published article, there was an error in (Figure 3H) as published. (Due to the error of data filing, the fluorescence images of the Erastin group in Figure 3H was inserted incorrectly). The corrected (Figure 3H) and its caption (Erastin initiated inflammation responses and ECM degradation in chondrocytes that could be alleviated by Ferrostatin-1) appear below. In the published article, there was an error in (Figure 5F) as published. (Due to the error of data filing, the fluorescence images of the Control group in Figure 5F was inserted incorrectly). The corrected (Figure 5F) and its caption (DFO alleviated chondrocytes ferroptosis and OA progress induced by erastin) appear below. In the published article, there was an error. (There is a clerical error in the Materials and Methods section). A correction has been made to (Materials and Methods), (Animal experiment). This sentence previously stated: “(the sham group, DMM group, DMM + DFO (10 mg/kg) group, DMM + DFO (100 mg/kg) group, erastin group, erastin (15 mg/kg) + DFO (10 mg/kg) group, and erastin (15 mg/kg) + DFO (100 mg/kg) group.)” The corrected sentence appears below: “(the sham group, DMM group, DMM + DFO (10 mg/kg) group, DMM + DFO (100 mg/kg) group, erastin group, erastin (5 mg/kg) + DFO (10 mg/kg) group, and erastin (5 mg/kg) + DFO (100 mg/kg) group.)” The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.